Articles in press

Background: Cellular senescence is a stress response, triggered by various stimuli such as chemotherapy treatment and causes G0/G1 cell cycle arrest followed by the production of a senescence associated secretory phenotype (SASP). p53 considered to be a modulator of these events although the precise mechanisms of it remains not clear. Aims: To determine the non-apoptotic functions of the p53 protein - the formation of the SASP phenotype of melanoma cells under the treatment of the cytostatic agent dacarbazine. Materials and methods: The study was conducted on BRO and SK-MEL-2 skin melanoma cell lines. Melanoma cells were were treated by cytostatic agent dacarbazine. Then immunocytochemical study was performed to determine the proportion of G0-positive cells and the expression of the tumor suppressor protein p53. A bioinformatic analysis was accomplished to identify for p53 regulators with determining of miR-155-5p levels in exosomes released by dacarbazine-treated melanoma cells. Results: The cytostatic drug dacarbazine increases the proportion of cells residing in the G0 phase of the cell cycle. Onco-microRNA miR-155-5p was expressed in the exosomes of the two studied cell lines BRO and SK-MEL-2 of skin melanoma. Changes in the expression level of p53 correlate with changes in miR-155-5p microRNA expression. The absence of changes in p53 expression in BRO melanoma cells may be due to the absence of changes in miR-155-5p expression levels. In the BRO cell line, no changes in the expression of the oncosuppressor p53 were observed with an increased percentage of G0-positive cells, which may be associated with the activation of other mechanisms of cell cycle arrest in the G0/G1 phase. Conclusions: Heterogeneous effect of the cytostatic agent dacarbazine on melanoma cells was revealed. For the SK-MEL-2 cell line, dacarbazine induces the release of senescence associated secretory phenotype by inhibiting exosomal production of miR-155-5p, which activates the p53 oncosuppressor, which was not observed in the BRO line. In this regard, there is a need for a more personalized approach to the treatment of malignant neoplasms.

Ruksha T., Dashkova D., Esimbekova A., Kotova K.
Russian Journal of Oncology.
views

The role of mitochondria in the development of breast cancer

Tikhonov D.G., Vinokurov M.M., Kipriyanova N.S., Golubenko M.V.
Russian Journal of Oncology.
views


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies